Russian scientists develop Ebola vaccine targeting DRC Bundibugyo strain
Synopsis
Russia has announced a vaccine targeting the Bundibugyo Ebola strain — the very variant driving a DRC outbreak with over 900 suspected cases and no approved treatment. If verified, it could be the first vaccine specifically designed for a strain that has so far left health authorities with no medical countermeasure beyond isolation.
Key Takeaways
Russian Health Minister Mikhail Murashko announced on 27 May that Russian scientists have developed a vaccine against the Bundibugyo Ebola strain .
The DRC outbreak has surpassed 900 suspected cases and 220 suspected deaths , with 101 confirmed cases and 10 confirmed deaths .
The outbreak was declared a public health emergency of international concern by the WHO on 17 May .
The epidemic has spread to Uganda , which has recorded five confirmed cases and one death .
There is currently no approved vaccine or treatment for the Bundibugyo strain; Russia's announcement has not yet been independently verified.
The average Ebola case fatality rate is approximately 50% , with past outbreaks ranging from 25% to 90% .
Russian scientists have developed a new vaccine targeting the Bundibugyo strain of the Ebola virus, the strain responsible for the deadly outbreak currently sweeping the Democratic Republic of Congo (DRC), Russian Health Minister Mikhail Murashko announced on Tuesday, 27 May. The development comes as the DRC outbreak — declared a public health emergency of international concern on 17 May — continues to accelerate, with no approved vaccine or specific treatment currently available for this strain.
What Russia Has Announced
The Russian Embassy in South Africa shared the announcement via its official account on X (formerly Twitter), stating that the vaccine may also offer protection against the rare Bundibugyo strain linked to the DRC epidemic. According to Russian scientists, the formulation is designed specifically to address this strain, which differs from the more widely studied Zaire strain that past approved vaccines targeted.
No timeline for clinical trials, regulatory approval, or deployment has been publicly confirmed. The announcement has not yet been independently verified by international health bodies.
Scale of the DRC Outbreak
World Health Organisation (WHO) Director-General Tedros Adhanom Ghebreyesus told a Virtual Ministerial Briefing on Monday, 26 May, that the outbreak's true scale far exceeds confirmed figures. 'There are now more than 900 suspected cases and 220 suspected deaths,' Tedros said. Confirmed cases stand at 101, with 10 confirmed deaths — a gap that health officials attribute to limited testing capacity in affected areas.
On Tuesday, DRC Health Minister Roger Kamba told a press conference that health authorities have identified around 1,000 suspected cases, of which 101 have tested positive. Kamba described the Bundibugyo strain as less lethal than the Zaire strain but warned that infections and deaths continue to rise.
Regional Spread and Emergency Status
The outbreak has crossed into Uganda, which has recorded five confirmed cases and one death, raising fears of wider regional transmission. The WHO declared the situation a public health emergency of international concern (PHEIC) on 17 May — a designation reserved for events with the potential for international spread and requiring a coordinated global response.
This comes amid a broader pattern: the DRC has historically been the epicentre of Ebola outbreaks, and the Bundibugyo strain — first identified in Uganda in 2007 — has previously caused outbreaks with case fatality rates ranging from 25% to 90%. The WHO places the average Ebola fatality rate at approximately 50%.
Why the Vaccine Gap Matters
Unlike the Zaire strain, for which approved vaccines such as rVSV-ZEBOV exist, the Bundibugyo strain currently has no approved vaccine or specific treatment. This has severely constrained the public health response in the DRC, where contact tracing and isolation remain the primary tools available to health workers.
The 2014–2016 West Africa outbreak — the largest in history — resulted in more cases and deaths than all previous Ebola outbreaks combined, spreading across Guinea, Sierra Leone, and Liberia. That crisis accelerated vaccine development for the Zaire strain; the current DRC emergency may similarly fast-track work on Bundibugyo-specific candidates.
Russia's announcement, if substantiated through peer review and international trials, could mark a significant turning point in the outbreak response. International health authorities are expected to seek further details on the vaccine's efficacy data and development stage.
Point of View
WHO-approved vaccine is vast. The DRC's Bundibugyo outbreak has exposed a critical blind spot in global health preparedness: decades of Ebola vaccine R&D have overwhelmingly focused on the Zaire strain, leaving Bundibugyo essentially unaddressed. Whether Moscow's claim holds up to peer scrutiny or becomes a geopolitical signal in a contested health diplomacy space is the question international observers should be pressing. The WHO's silence on the Russian announcement, as of publication, is notable.
NationPress
13 Jul 2026
Frequently Asked Questions
What vaccine have Russian scientists developed for Ebola?
Russian scientists have developed a vaccine targeting the Bundibugyo strain of the Ebola virus, according to an announcement by Russian Health Minister Mikhail Murashko on 27 May. The vaccine reportedly may also offer protection against the rare Bundibugyo strain linked to the ongoing DRC outbreak, though it has not yet been independently verified by international health bodies.
How serious is the current Ebola outbreak in the DRC?
The DRC Ebola outbreak has recorded more than 900 suspected cases and 220 suspected deaths as of 26 May, according to WHO Director-General Tedros Adhanom Ghebreyesus. The WHO declared it a public health emergency of international concern on 17 May, and the outbreak has since spread to Uganda.
Why is the Bundibugyo Ebola strain particularly dangerous right now?
The Bundibugyo strain currently has no approved vaccine or specific treatment, making containment entirely dependent on isolation and contact tracing. While DRC Health Minister Roger Kamba described it as less lethal than the Zaire strain, he warned that rising infections and deaths pose a serious public health risk.
Has the Ebola outbreak spread beyond the DRC?
Yes. Uganda has recorded five confirmed cases and one death, indicating cross-border transmission. The WHO's PHEIC declaration reflects concern about the outbreak's potential for further international spread.
What is the fatality rate for Ebola?
According to the WHO, the average Ebola case fatality rate is approximately 50%, though rates in past outbreaks have ranged from 25% to 90% depending on the strain and response capacity. The 2014–2016 West Africa outbreak was the deadliest in history, with more deaths than all previous outbreaks combined.
